75 related articles for article (PubMed ID: 27561802)
1. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
[TBL] [Abstract][Full Text] [Related]
2. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
[TBL] [Abstract][Full Text] [Related]
3. Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings.
Dong W; Zhuge J; Yu P; Liu K; Yang M; Wang H
Medicine (Baltimore); 2023 Dec; 102(51):e36591. PubMed ID: 38134118
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Gerlinger M; Norton L; Swanton C
N Engl J Med; 2013 Sep; 369(12):1172-3. PubMed ID: 24047073
[No Abstract] [Full Text] [Related]
5. Molecular pathways: ROS1 fusion proteins in cancer.
Davies KD; Doebele RC
Clin Cancer Res; 2013 Aug; 19(15):4040-5. PubMed ID: 23719267
[TBL] [Abstract][Full Text] [Related]
6. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
Jenkins RW; Oxnard GR; Elkin S; Sullivan EK; Carter JL; Barbie DA
Clin Lung Cancer; 2015 Sep; 16(5):e101-4. PubMed ID: 25769807
[No Abstract] [Full Text] [Related]
7. Clinical activity of crizotinib in lung adenocarcinoma harboring a
Kinoshita R; Nakao M; Kiyotoshi H; Hayashi S; Sugihara M; Hirata Y; Kuriyama M; Takeda N; Muramatsu H
Oncol Lett; 2023 Dec; 26(6):515. PubMed ID: 37927416
[TBL] [Abstract][Full Text] [Related]
8. Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors.
Carcamo B; Bista R; Wilson H; Reddy P; Pacheco J
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e718-e722. PubMed ID: 34157012
[TBL] [Abstract][Full Text] [Related]
9. Multiple cerebral infarctions in
Ikushima H; Hiraishi Y; Toriumi K; Ando T; Tamiya H; Ishida J; Amano Y; Kage H; Tanaka G; Nagase T
Respirol Case Rep; 2021 Sep; 9(9):e0831. PubMed ID: 34471540
[TBL] [Abstract][Full Text] [Related]
10. Extraordinary linear non-enhancing brainstem leptomeningeal metastasis from lung adenocarcinoma: A case report.
Tan Z; Lin SZZ; Li Y; Kheok SW
Clin Case Rep; 2024 May; 12(5):e8932. PubMed ID: 38751962
[TBL] [Abstract][Full Text] [Related]
11. Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma.
Wei S; Zhang ZY; Fu SL; Xie JG; Liu XS; Xu YJ; Zhao JP; Xiong WN
Cell Death Dis; 2016 Sep; 7(9):e2388. PubMed ID: 27685632
[TBL] [Abstract][Full Text] [Related]
12. Two-stage induced differentiation of OCT4+/Nanog+ stem-like cells in lung adenocarcinoma.
Li R; Huang J; Ma M; Lou Y; Zhang Y; Wu L; Chang DW; Zhao P; Dong Q; Wu X; Han B
Oncotarget; 2016 Oct; 7(42):68360-68370. PubMed ID: 27588392
[TBL] [Abstract][Full Text] [Related]
13. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
[TBL] [Abstract][Full Text] [Related]
14. Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.
Chang X; Liu Z; Man S; Roys A; Li Z; Zuo D; Wu Y
RSC Adv; 2019 Jun; 9(31):17921-17932. PubMed ID: 35520562
[TBL] [Abstract][Full Text] [Related]
15. Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer.
Okawa S; Shibayama T; Shimonishi A; Nishimura J; Ozeki T; Takada K; Kayatani H; Minami D; Sato K; Fujiwara K; Yonei T; Sato T; Suno M
Case Rep Oncol; 2018; 11(3):777-783. PubMed ID: 30627092
[TBL] [Abstract][Full Text] [Related]
16. [Crizotinib Treatment Combined with Resection and Whole-brain Radiation Therapy
in A ROS1 Rearranged Lung Adenocarcinoma with Brain Metastasis:
Case Report and Literature Review].
Zhang M; Nie L; Zhang J
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):525-9. PubMed ID: 27561802
[TBL] [Abstract][Full Text] [Related]
17. [Crizotinib treatment in a lung adenocarcinoma harboring ALK fusion gene with bone marrow metastasis: case report and literature review].
Li X; Liu X; Gao F; Yin X
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):85-8. PubMed ID: 25676401
[TBL] [Abstract][Full Text] [Related]
18. Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review.
Liu L; Wu J; Zhao W; Huang MJ
Medicine (Baltimore); 2017 May; 96(21):e6979. PubMed ID: 28538401
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
